FREQUENCY OF HUMAN CYP2D6 MUTANT ALLELES IN A NORMAL CHINESE POPULATION

被引：26

作者：

LEE, EJD ^{[1
]}

JEYASEELAN, K ^{[1
]}

机构：

[1] NATL UNIV SINGAPORE,DEPT BIOCHEM,SINGAPORE 0511,SINGAPORE

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1994年 / 37卷 / 06期

关键词：

GENETIC POLYMORPHISM; CYP2D6; CHINESE CYTOCHROME P450;

D O I：

10.1111/j.1365-2125.1994.tb04311.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Substantial differences in the pharmacogenetics of debrisoquine hydroxylation exist between Caucasians and Chinese populations. Among Chinese, not only is the frequency of the poor metabolizer phenotype low, the contribution of the 29B mutation in the CYP2D6 gene is insignificant. By contrast the frequency of D6-J is very common (similar to 0.6) and is clearly related to the activity of debrisoquine hydroxylase. Its presence however, does not predict the poor metabolizer phenotype. The D6-C mutation was also not detectable in our population.

引用

页码：605 / 607

页数：3

共 50 条

[21] CYP2D6: novel genomic structures and alleles
Kramer, Whitney E.
Walker, Denise L.
O'Kane, Dennis J.
Mrazek, David A.
Fisher, Pamela K.
Dukek, Brian A.
Bruflat, Jamie K.
Black, John L.
PHARMACOGENETICS AND GENOMICS, 2009, 19 (10): : 813 - 828
[22] CYP2D6 polymorphism in Chinese breast cancer population.
Li, Kai
Liao, Ning
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[23] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
Abduljalil, K.
Frank, D.
Gaedigk, A.
Klaassen, T.
Tomalik-Scharte, D.
Jetter, A.
Jaehde, U.
Kirchheiner, J.
Fuhr, U.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
[24] Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population
Buzkova, Helena
Pechandova, Kristina
Slanar, Ondrej
Perlik, Frantisek
CELL BIOCHEMISTRY AND FUNCTION, 2008, 26 (01) : 76 - 81
[25] Frequency of mutated allele CYP2D6*4 in the Turkish population
Koseler, Aylin
Ilcol, Yesim Ozarda
Ulus, Ismail H.
PHARMACOLOGY, 2007, 79 (04) : 203 - 206
[26] Effects of CYP2D6*10 and CYP2D6*5 alleles on the pharmacokinetics of carvedilol in healthy Koreans.
Kang, Byung-Sung
Lee, Hye-In
Choi, Chang-Ik
PHARMACOTHERAPY, 2012, 32 (10): : E301 - E301
[27] Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients:: therapeutic consequences?
Haffen, E
Vandel, P
Paintaud, G
Broly, F
Vandel, S
Bonin, B
Bizouard, P
Sechter, D
Bechtel, PR
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 55 (11-12) : 877 - 879
[28] Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: therapeutic consequences?
E. Haffen
P. Vandel
G. Paintaud
F. Broly
S. Vandel
B. Bonin
P. Bizouard
D. Sechter
P. R. Bechtel
European Journal of Clinical Pharmacology, 2000, 55 : 877 - 879
[29] Polymorphism of CYP2D6 alleles in Parkinson's disease
Lisak, M.
Stefanovic, M.
Bedekovic, M. Roje
Trkanjec, Z.
Demarin, V.
MOVEMENT DISORDERS, 2009, 24 : S145 - S145
[30] Effect of different alleles on CYP2D6 activity.
Borges, S
Jones, DR
Bermes, A
Skaar, TC
Hall, SD
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P25 - P25

← 1 2 3 4 5 →